Patrick P. Fourteau
Chief Executive Officer at New Haven Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Larry Dillaha | M | 60 |
Shionogi Pharma, Inc.
 Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA.
New Haven Pharmaceuticals, Inc.
 New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT. | 11 years |
| Harry Penner | M | 78 |
New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT. | 16 years |
| Nancy C. Motola | M | 71 |
New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT. | - |
| Daniel Wagner | M | 53 |
New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT. | - |
| Ambrose Bailey | M | 60 | 6 years | |
| William Sessa | M | - |
New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT. | - |
| Arthur Edwards | M | - |
New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT. | - |
| Michael Milligan | M | - |
New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT. | - |
| Stephen Kaufhold | M | - | 6 years | |
| Kira Schwartz | F | - | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John N. Kapoor | M | 80 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 27 years |
| Daniel Starks | M | 69 | 21 years | |
| Michael L. Babich | M | 47 |
InSys Therapeutics, Inc. /Old/
 InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 8 years |
| Jaye L. Thompson | M | 58 | 8 years | |
| Andrew Long | M | 58 | 2 years | |
| Michael Rousseau | M | 68 | - | |
| Joseph S. Podolski | M | 76 | 28 years | |
| Franc E. Del Fosse | M | 52 | - | |
| Nola Masterson | F | 77 | 14 years | |
| Katherine A. Anderson | F | 66 | 16 years | |
| Mahendra Shah | M | 79 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 10 years |
| Martin K. McCarthy | M | 65 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 5 years |
| Saeed Motahari | M | 58 | 2 years | |
| Paul Mignon | M | - |
inVentiv Health, Inc.
 inVentiv Health, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health, Inc. provides outsourced product development and commercialization services. It operates its business through the following segments: Clinical and Commercial. The Clinical segment clinical offers a continuum of services spanning phases I-IV of clinical development to the changing needs of pharmaceutical, biotechnology, diagnostic and medical device clients. The Commercial segment consists of selling solution services, communications, patient outcomes and consulting service offerings. The company was founded in 1999 and is headquartered in Burlington, MA. | - |
| John Heinmiller | M | 69 | 21 years | |
| Sona Saira Ramasastry | F | 48 | 5 years | |
| Richard Mallery | M | 86 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | - |
| Scott P. Thome | M | 61 | 19 years | |
| Michael Wyllie | M | 73 | 7 years | |
| Andrew Balo | M | 76 | 7 years | |
| Rohit Vishnoi | M | 63 | - | |
| Stuart Essig | M | 62 | 18 years | |
| John R. Emery | M | 67 |
inVentiv Health, Inc.
inVentiv Health, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health, Inc. provides outsourced product development and commercialization services. It operates its business through the following segments: Clinical and Commercial. The Clinical segment clinical offers a continuum of services spanning phases I-IV of clinical development to the changing needs of pharmaceutical, biotechnology, diagnostic and medical device clients. The Commercial segment consists of selling solution services, communications, patient outcomes and consulting service offerings. The company was founded in 1999 and is headquartered in Burlington, MA. | - |
| Daniel Douglas von Hoff | M | 76 | - | |
| Andrece Housley | M | 56 | - | |
| Terry L. Shepherd | M | - | 5 years | |
| Daniel F. Cain | M | 79 | 14 years | |
| Jon W. McGarity | M | 82 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 1 years |
| Darryl S. Baker | M | 55 | - | |
| Santosh Vetticaden | M | 65 | 2 years | |
| Edward Schutter | M | 72 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 2 years |
| Patrick Zenner | M | 77 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 6 years |
| Ramesh Acharya | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | - |
| Ashok J. Chavan | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | - |
| John Alexander | M | - | 3 years | |
| William O'Donnell | M | - |
inVentiv Health, Inc.
inVentiv Health, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health, Inc. provides outsourced product development and commercialization services. It operates its business through the following segments: Clinical and Commercial. The Clinical segment clinical offers a continuum of services spanning phases I-IV of clinical development to the changing needs of pharmaceutical, biotechnology, diagnostic and medical device clients. The Commercial segment consists of selling solution services, communications, patient outcomes and consulting service offerings. The company was founded in 1999 and is headquartered in Burlington, MA. | - |
| Nat Krishnamurti | M | 53 |
inVentiv Health, Inc.
inVentiv Health, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health, Inc. provides outsourced product development and commercialization services. It operates its business through the following segments: Clinical and Commercial. The Clinical segment clinical offers a continuum of services spanning phases I-IV of clinical development to the changing needs of pharmaceutical, biotechnology, diagnostic and medical device clients. The Commercial segment consists of selling solution services, communications, patient outcomes and consulting service offerings. The company was founded in 1999 and is headquartered in Burlington, MA. | 11 years |
| Steven J. Meyer | M | 67 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 4 years |
| Ariyapadi N. Krishnaraj | M | - | - | |
| Todd F. Davenport | M | 73 | 3 years | |
| Jerry N. Ellis | M | 86 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 8 years |
| James E. Machek | M | 66 | 10 years | |
| Pierre LaPalme | M | 83 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 8 years |
| John Harris | M | 76 |
inVentiv Health, Inc.
inVentiv Health, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health, Inc. provides outsourced product development and commercialization services. It operates its business through the following segments: Clinical and Commercial. The Clinical segment clinical offers a continuum of services spanning phases I-IV of clinical development to the changing needs of pharmaceutical, biotechnology, diagnostic and medical device clients. The Commercial segment consists of selling solution services, communications, patient outcomes and consulting service offerings. The company was founded in 1999 and is headquartered in Burlington, MA. | 8 years |
| Daniel Brennan | M | 56 | 1 years | |
| Steven James | M | - | - | |
| Brian Jennings | M | - | - | |
| Dean Mariano | M | - | 2 years | |
| Scott Warlick | M | - | 3 years | |
| Joe McGrath | M | - | 1 years | |
| Steve Sherman | M | - | 5 years | |
| Jeff Del Carmen | M | 53 | - | |
| Denis M. Gestin | M | 60 | 20 years | |
| Troy Ignelzi | M | 56 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 2 years |
| Stephen E. Butts | M | - |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | - |
| Jeri L. Lose | F | 66 | - | |
| Joseph Ciaffoni | M | 53 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 2 years |
| Frank C. Becker | M | 88 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 7 years |
| Eric M. Heer | M | 53 | 2 years | |
| David Thompson | M | 82 | - | |
| Eric Fain | M | 63 | - | |
| Paul Freiman | M | 89 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 7 years |
| Stephen L. Wilson | M | 70 | 7 years | |
| Jerry Griffin | M | 79 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 2 years |
| Steven Michael Anderson | M | 61 | 9 years | |
| Van A. Frazier | M | 71 | 2 years | |
| Ted H. Stanley | M | 83 | 4 years | |
| Jon Saxe | M | 88 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 8 years |
| William John Robinson | M | 76 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 4 years |
| Leslie B. Zacks | M | 55 |
Shionogi Pharma, Inc.
Shionogi Pharma, Inc. Pharmaceuticals: MajorHealth Technology Shionogi Pharma, Inc. manufactures pharmaceuticals. The company is headquartered in Alpharetta, GA. | 6 years |
| Katherine S. Tweden | M | 63 | 7 years | |
| Bernard A. Fox | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 7 years |
| Michael J. Girard | M | - | 8 years | |
| Eric W. Sivertson | M | 73 | 11 years | |
| Robert E. Munzenrider | M | 79 | 1 years | |
| Christopher F. Homrich | M | - | - | |
| Michael L. Hlinak | M | - |
inVentiv Health, Inc.
inVentiv Health, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health, Inc. provides outsourced product development and commercialization services. It operates its business through the following segments: Clinical and Commercial. The Clinical segment clinical offers a continuum of services spanning phases I-IV of clinical development to the changing needs of pharmaceutical, biotechnology, diagnostic and medical device clients. The Commercial segment consists of selling solution services, communications, patient outcomes and consulting service offerings. The company was founded in 1999 and is headquartered in Burlington, MA. | 12 years |
| Venkat Reddy Goskonda | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | - |
| Mark Kroll | M | 71 | 10 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 89 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patrick P. Fourteau
- Personal Network
